Loading
ESMO 2022

ESMO 2022

European Society for Medical Oncology Congress 2022
Leah Lawrence

ESMO 2022 | September 16, 2022

Neoadjuvant platinum-based chemotherapy has been found effective for treating metastatic penile squamous cell carcinoma.

Leah Lawrence

ESMO 2022 | September 16, 2022

A new study has found an association between neurodevelopmental disorders and testicular seminoma.

Leah Lawrence

ESMO 2022 | September 16, 2022

CLEAR study results showed that treatment with first-line lenvatinib plus pembrolizumab had clinical benefit at 2 years.

Leah Lawrence

ESMO 2022 | September 16, 2022

The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.

Patrick Daly

ESMO 2022 | September 14, 2022

Patients with mCRPC with AR alterations had significantly worse survival outcomes compared with patients with wild-type.

Patrick Daly

ESMO 2022 | September 14, 2022

A meta-analysis found that triplet regimens with darolutamide and APP improved survival in mCSPC with high volume of disease.

Patrick Daly

ESMO 2022 | September 14, 2022

Pembro plus AAP sustained antitumor activity with acceptable safety signals in patients with mCRPC after 2 years.

Patrick Daly

ESMO 2022 | September 14, 2022

PRESTO trial results show adding APA and AAP to ADT improved biochemical PFS in patients with relapsed prostate cancer.

Patrick Daly

ESMO 2022 | September 12, 2022

177Lu-PSMA-RLT showed efficacy and safety consistent with published evidence in cohort of very old patients with mCRPC.

Patrick Daly

ESMO 2022 | September 12, 2022

Karim Fizazi discussed preliminary findings on ODM-208, a first-in-class CYP11A1 inhibitor at ESMO 2022.

Patrick Daly

ESMO 2022 | September 12, 2022

Late-breaking data from 2 randomized phase 3 trials that followed STAMPEDE protocol were presented at the ESMO Congress 2022.

Patrick Daly

ESMO 2022 | September 10, 2022

Researchers evaluated immune effects of enzalutamide in patients with metastatic castration-resistant prostate cancer on ADT.

Patrick Daly

ESMO 2022 | September 10, 2022

Pembrolizumab plus olaparib did not improve survival versus alternating from abiraterone or enzalutamide in mCRPC.

Patrick Daly

ESMO 2022 | September 10, 2022

This randomized controlled trial was part of a series of trials conducted under the RADICALS protocol.

Patrick Daly

ESMO 2022 | September 10, 2022

Researchers reported the impact of hormone therapy on survival in patients with prostate cancer undergoing radiotherapy.

Emily Menendez

ESMO 2022 | September 10, 2022

By the end of the trial, 78% of the patients remained event-free, with an rPFS rate of 75.4% at 9 months.